Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211
This study is recruiting at 11 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Endometrial Cancer
- Gastric Cancer
- Metastatic Castration-resistant Prostate Cancer
- Ovarian Cancer
- Colorectal Cancer
- Urothelial Cancer
- Biliary Tract Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 130 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- September 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Research Site · Los Angeles, CA
- Research Site · Santa Rosa, CA
Michigan · 1
- Research Site · Grand Rapids, MI
New Jersey · 1
- Research Site · East Brunswick, NJ
New Mexico · 1
- Research Site · Albuquerque, NM
New York · 1
- Research Site · Commack, NY
Ohio · 2
- Research Site · Cincinnati, OH
- Research Site · Columbus, OH
Tennessee · 1
- Research Site · Nashville, TN
Texas · 1
- Research Site · Houston, TX
Wisconsin · 1
- Research Site · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.